CELL Technologies Inc. has submitted clinical data from its stem cell program for pain management to Health Canada for approval. This follows a regulatory meeting on March 31st, 2023, and if approved, CELL would become the first regulatory-approved stem cell provider in North America. The data submitted covers three studies in arthritis, degenerative disc disease, and back pain.
The program aims to give Canadian patients access to evidence-based and regulatory-approved stem cell procedures for pain management. According to Dr. Riam Shammaa, CEO of CELL, this is a significant milestone in providing patients with life-changing procedures without having to travel abroad or endure high costs for unvalidated treatments.
Over the past decade, CELL has conducted early and comparative clinical studies at the Canadian Centre for Regenerative Therapy. Dr. Gregory Murphy, Chief Medical Officer of CELL, shared that the published clinical studies demonstrated robust safety and efficacy, including a 60% reduction in arthritis pain, an 85% success rate in repairing degenerated lumbar spine discs, and 60% of patients discontinuing opioids after treatment.
CELL plans to file an application to initiate a national pivotal clinical program by Q3 2023. The company is a clinical-stage biotech firm specializing in stem cell therapy for pain medicine and inflammatory conditions. Its platform is based on proprietary technology developed through more than 10 years of research in cell therapy, and includes both autologous and allogeneic programs.
SOURCE Cell Technologies Inc.